Health In Tech Inc Dossier - Source-backed chat

Health In Tech Inc

HITNASDAQ

SectorFinancials

IndustryInsurance Brokers

Beta (adjusted)2.22

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.74Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $48.3M

Enterprise Value $41.9M

Shares Outstanding 60.8M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Health In Tech, Inc. (NASDAQ: HIT) is a rapidly growing, AI-enabled InsurTech platform that streamlines the self-funded and level-funded health insurance marketplace. By vertically integrating underwriting, sales, and administrative workflows, the company compresses traditional quoting timelines from months to minutes. Despite near-term margin pressures from public company transition costs and aggressive sales investments, the company's massive 71% year-over-year revenue growth in 2025 and strong forward guidance of $45M–$50M for 2026 demonstrate robust market demand and scalability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.70

High · most bullish analyst$4.10

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.85

Intense competition in the highly regulated healthcare sector slows broker onboarding, and the transition to larger employer segments faces execution delays. High customer acquisition costs and elevated R&D capitalization write-offs pressure liquidity, forcing the company to rely on dilutive capital raises under its shelf registration statement.

Base CaseCentral scenario

$4.03

Health In Tech successfully executes its core strategy, achieving 2026 revenue within the guided range of $45M–$50M (representing 35% to 50% YoY growth). The distribution network of brokers and TPAs continues to expand at a double-digit rate, and the company maintains positive operating cash flow while gradually narrowing quarterly net losses as public company infrastructure costs stabilize.

Bull CaseUpside scenario

$4.59

Rapid adoption of the eDIYBS platform among larger employers (100+ employees) and successful monetization of its proprietary data lake drive revenue well above the high end of 2026 guidance. Differentiated products like the Three-Year Rate Stabilization Program significantly improve client retention and attract premium carriers, leading to operating leverage and an expansion of Adjusted EBITDA margins toward 15%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line momentum with 71% YoY revenue growth in 2025 to $33.33 million.
Proprietary eDIYBS technology that compresses underwriting timelines for self-funded plans from 3 months to 2 weeks.
Expanding distribution footprint with an 858-partner network of brokers, TPAs, and agencies (up 34% YoY).
High revenue visibility with $22.9 million in contracted revenue secured for the remaining three quarters of 2026 as of Q1.

Key Investment Risks

Near-term profitability challenges, highlighted by a Q1 2026 Adjusted EBITDA of $(1.3) million due to heavy sales and marketing reinvestment.
Substantial execution and regulatory risks inherent in the complex, non-transparent US healthcare and insurance sector.
Potential equity dilution from the active $300 million shelf registration statement filed in June 2026.

Thesis Invalidation Triggers

Failure to achieve the lower bound of the FY 2026 revenue guidance ($45 million).
A significant decline in the broker and TPA partner growth rate, indicating a loss of platform competitive advantage.
Severe regulatory changes restricting self-funded or level-funded health insurance structures.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.